IVIG Costs $30,000 a Month. Here Is What Patients Actually Pay.

The patient described below is an illustrative composite, not a real individual.

When the approval letter finally arrived for Carol M., a 62-year-old retired teacher in suburban Ohio, her neurologist had been fighting her insurer for three months to authorize Privigen for her CIDP — chronic inflammatory demyelinating polyneuropathy, a progressive nerve disorder that had left her unable to climb stairs without help. The letter read "approved." Two weeks later, her specialty pharmacy called with the out-of-pocket estimate: just under $4,000 for the first month.

She had Medicare. She had a supplement. She had waited 90 days.

Four thousand dollars was not the number she expected. It was not the number anyone told her to prepare for. And it was, by the mechanics of how IVIG is priced and billed, completely predictable — if you know where to look.

The List Price Nobody Pays, and the Patient Who Mostly Does

IVIG — intravenous immunoglobulin — is derived from pooled human plasma, manufactured in large quantities, and priced accordingly. The branded products most commonly used for neurological and immunological indications — Privigen, Gamunex-C, and Hizentra (the subcutaneous formulation) — carry Wholesale Acquisition Costs (WAC) in the range of $60 to $110 per gram, according to published manufacturer pricing and specialty pharmacy industry data. A patient with CIDP or primary immunodeficiency who requires a body-weight-based dose may receive anywhere from 25 to 100 grams per infusion, with infusions every three to four weeks.

At those parameters, the math runs fast. A single infusion for a mid-weight patient at average dose levels can carry a WAC of $3,000 to $8,000. Monthly maintenance therapy for CIDP or PIDD commonly reaches $20,000 to $50,000 at list, according to the Immune Deficiency Foundation and published clinical cost analyses. Annual expenditure at list price can exceed $300,000 for patients with high dose requirements.

No insurer pays WAC. The negotiated rate between manufacturers and payers — commercial, Medicare, and Medicaid — is significantly lower. But the negotiated rate is not what determines what the patient pays. The patient's cost-sharing structure determines that. And the relationship between list price, negotiated rate, and patient liability is the part of the cost chain that is rarely explained clearly.

The Cost Chain: From Manufacturer to Patient Bill

The journey from manufacturer list price to patient out-of-pocket involves several pricing layers, and the patient's share is determined at the end of a long chain of negotiations they were not part of.

Manufacturer WAC is the starting point — the baseline price before any discounts, rebates, or contract adjustments.

Insurer negotiated rate (for commercial plans) or ASP-based reimbursement (for Medicare Part B) represents the amount the payer actually reimburses to the provider or facility for the drug. Under Medicare Part B, IVIG is reimbursed at the Average Sales Price plus a 6% add-on, known as ASP+6. ASP is calculated quarterly by CMS from manufacturer-reported data and is generally lower than WAC, though the exact relationship varies by product and quarter.

Patient cost-sharing is calculated as a percentage of either the negotiated rate (commercial) or the allowed amount (Medicare). This is where the patient's actual bill originates.

Medicare Part B: The 20% Problem

IVIG administered in a clinical setting is covered under Medicare Part B as a medical benefit, not a pharmacy benefit. This is the J-code billing pathway — the product is billed by the provider or facility alongside the infusion service.

Under traditional Medicare, the patient is responsible for 20% of the Medicare-allowed amount for the drug after the annual Part B deductible ($240 in 2024). There is no out-of-pocket maximum under traditional Medicare Part B. For a patient receiving $12,000 per month in IVIG (at the Medicare-allowed amount), the monthly liability is approximately $2,400. Annually, that is $28,800.

Medicare Advantage plans may structure IVIG cost-sharing differently, with some offering lower coinsurance or an out-of-pocket maximum that traditional Medicare does not have. The specific structure varies significantly by plan. Medigap supplement plans (particularly Plans G and N) cover the Part B coinsurance, which is the primary reason neurologists and immunologists often counsel their Medicare patients about Medigap enrollment — the financial exposure on biological infusion therapies can otherwise be substantial.

The patient in Carol's case had a Medigap plan that covered most of her coinsurance. The $4,000 estimate reflected the window before her deductible was met, plus administrative fees at her infusion center. That number drops dramatically once the deductible clears. But in January, it is always January.

Commercial Insurance: The Specialty Tier

For patients under 65 with commercial insurance, IVIG typically lands in the specialty tier of the formulary — Tier 4 or Tier 5, with coinsurance that often runs 20% to 33% of the plan's allowed amount. Prior authorization is nearly universal for IVIG across commercial plans.

Step therapy requirements are common and clinically contentious. Some plans require documented failure of subcutaneous immunoglobulin (SCIG) before approving IV administration, a protocol that neurologists treating CIDP frequently dispute on clinical grounds — the absorption kinetics and patient management of SCIG are not equivalent to IVIG for all patients, and the level of care required for self-administered subcutaneous therapy is not appropriate for all clinical situations.

Prior authorization must typically be renewed every six months, meaning that patients who have been stable on IVIG for years face re-authorization cycles that can result in gaps in therapy. A 2022 AMA survey found that 94% of physicians reported that prior authorization requirements delay patient access to care. For a patient who requires immunoglobulin supplementation for primary immunodeficiency, a gap in therapy is not a scheduling inconvenience.

Site of Care: Where You Receive the Infusion Changes the Bill

One of the least-discussed variables in IVIG cost is the site of care — specifically, whether the infusion is administered in a hospital outpatient department, a freestanding specialty infusion center, or at home.

Hospital outpatient infusion carries the highest facility fees. A CMS analysis of site-of-care pricing differentials across drug categories consistently shows significant cost gaps between hospital outpatient and alternative care sites. Insurers are increasingly applying site-of-care policies that require or incentivize patients to use lower-cost settings — home infusion or freestanding infusion centers — rather than hospital outpatient departments.

For patients on long-term IVIG therapy, this can mean that a payer approves the drug but steers the patient toward a lower-cost site that may not be clinically appropriate for their condition or practically accessible given their geography and functional status. Step-down to home infusion requires that a patient can self-administer or have a caregiver available, and that home nursing support is arranged. Not all patients on IVIG qualify for or can safely manage home infusion.

Site-of-care denials are a specific category of appeal — distinct from medical necessity denials — and are increasingly common in commercial IVIG coverage.

Copay Cards, Accumulators, and the Federal Firewall

Manufacturer copay assistance programs for branded IVIG products are available for commercially insured patients, and can substantially reduce or eliminate monthly out-of-pocket costs. Privigen, Gamunex-C, and Hizentra each have manufacturer patient support programs with copay assistance components.

These programs do not work for Medicare, Medicaid, or TRICARE beneficiaries. Federal anti-kickback statute prohibits manufacturers from subsidizing cost-sharing for government program beneficiaries. For the CIDP patient on traditional Medicare, manufacturer copay assistance is not available.

For commercial patients, copay accumulator programs present a second complication. An accumulator intercepts the manufacturer's copay card payment and prevents it from counting toward the patient's deductible and out-of-pocket maximum. This means a patient who uses a copay card for the first six months of the year and then exhausts the card benefit faces the full deductible and out-of-pocket maximum in the back half of the year — with no credit for the assistance the manufacturer already provided. Specialty pharmacies that work extensively with IVIG products are generally aware of which commercial plans use accumulators, and can flag the risk before it becomes a year-end surprise.

Foundation Assistance: The Funds That Can Bridge the Gap

Several nonprofit foundations maintain funds specifically for immunoglobulin therapy patients.

The Immune Deficiency Foundation (IDF) offers financial assistance information and connects patients with available programs. The IG Living Foundation maintains a resource directory for patients receiving immunoglobulin therapy, including foundation assistance programs. The PAN Foundation and HealthWell Foundation both maintain disease-specific funds, some of which cover IVIG-related cost-sharing; fund availability varies by year and application period.

Foundation funds open and close throughout the year based on available resources. Applying in the first quarter of the year, when many funds open new enrollment periods, is generally more likely to result in funding than applying in the third quarter when fund balances are often depleted.

For Medicare patients, these independent foundations are frequently the primary mechanism for covering Part B coinsurance that Medigap does not reach. They are not a permanent solution. They are, for many patients, what makes the math work.

The Denial Pattern

IVIG denials cluster around predictable categories: quantity limits (when the prescribed dose exceeds the plan's standard parameters), step therapy requirements (IV before sub-Q or sub-Q before IV, depending on the plan), re-authorization denials after a period of stable therapy, and site-of-care conflicts.

The re-authorization pattern is particularly problematic for patients with CIDP and other chronic neurological conditions where the clinical evidence of necessity was established at the time of initial authorization and may not have changed. Insurers require documented clinical justification at each renewal, and patients who have been stable often struggle to produce the same clinical urgency that drove the initial approval. Some neurologists address this by documenting what the patient's status would likely be without the therapy, not just what it is with it.

The appeal language for these denials follows the same framework as other prior authorization appeals: respond directly to the stated denial reason, cite clinical guidelines, document the individual clinical case. For IVIG specifically, the Immune Deficiency Foundation and the Peripheral Nerve Society both maintain clinical practice guidelines that carry weight in coverage appeals for CIDP and PIDD.

What the Bill Actually Says

Carol's January bill resolved differently than she feared. Her Medigap plan covered most of the Part B coinsurance once her deductible cleared. A patient assistance coordinator at her infusion center connected her with a HealthWell fund that covered the remainder for that year. She did not know any of this was available until she called the infusion center's billing department and asked specifically whether financial assistance existed.

The bill that arrived in February was $0. Nothing in her insurance paperwork told her that was possible.

The cost chain for IVIG is long, and most of it is invisible to the patient sitting in the infusion chair. The list price is not the negotiated rate. The negotiated rate is not the allowed amount. The allowed amount is not what the patient pays. And what the patient pays, before foundation assistance is applied, is not necessarily the final number.

None of this is disclosed at the pharmacy window.

Sources: Immune Deficiency Foundation, "IVIG Therapy Access and Reimbursement Guide," 2023; IG Living Foundation, patient resource library; CMS, "Medicare Part B Drug Payment Policy Issues," 2024; CMS, Average Sales Price quarterly drug pricing files; American Medical Association, "2024 Prior Authorization Physician Survey"; PAN Foundation; HealthWell Foundation; Peripheral Nerve Society, "PNS Evidence-Based Guideline on CIDP," 2023; manufacturer prescribing information and patient assistance program documentation (CSL Behring, Grifols USA).